{"analyses":[{"ciLowerLimit":"0.38","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.65","estimateComment":"Hazards ratio estimate is based on a Cox´s model stratified by IPI risk and stage of disease. A hazard ratio \\< 1 indicates an advantage for VcR-CAP.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","paramType":"Hazard Ratio (HR)","paramValue":"0.50","statisticalComment":"Based on Log rank test stratified with IPI risk and stage of disease.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"674.0","upperLimit":"837.0","value":"756.0"},{"comment":"The upper limit of the confidence interval was not able to be estimated.","groupId":"OG001","lowerLimit":"1180.0","upperLimit":"NA","value":"1353.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"243"}],"units":"Participants"}],"description":"The time to next anti-lymphomatreatment was measured from the date of initiation of study treatment as per protocol to the start date of new anti-lymphoma treatment. Death due to disease progression prior to subsequent therapy was considered as an event. Otherwise, time to next anti lymphoma treatment was censored at the date of death or the last date known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Rituximab 375 mg/m\\^2, Cyclophosphamide 750 mg/m\\^2, Doxorubicin 50 mg/m\\^2, Vincristine 1.4 mg/m\\^2 and Prednisone 100 mg/m\\^2 Rituximab: Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles. Cyclophosphamide: Cyclophosphamide intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Doxorubicin: Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Prednisone: Prednisone orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles Vincristine: Vincristine intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles.","id":"OG000","title":"R-CHOP"},{"description":"Rituximab 375 mg/m\\^2, Cyclophosphamide 750 mg/m\\^2, Doxorubicin 50 mg/m\\^2, VELCADE 1.3 mg/m\\^2, and Prednisone 100 mg/m\\^2 Rituximab: Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles. Cyclophosphamide: Cyclophosphamide intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Doxorubicin: Intravenous on Day of a 21 day (3 week) cycle for 6 cycles VELCADE: VELCADE intravenous on Days 1,4,8, and 11 of a 21 day (3 week) cycle for 6 cycles Prednisone: Prednisone orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles.","id":"OG001","title":"VcR-CAP"}],"paramType":"MEDIAN","populationDescription":"The population consisted of all randomized participants.","reportingStatus":"POSTED","timeFrame":": Median duration of follow-up of 40 months","title":"Time to Next Anti-lymphoma Treatment (TTNT)","type":"SECONDARY","unitOfMeasure":"Days"}